New drug takes aim at Hard-to-Treat cancers that reach the brain

NCT ID NCT06136884

First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 24 times

Summary

This early-stage study tests an experimental drug called AO-252 in people with advanced solid tumors (cancers) that have spread to the brain or other parts of the body. The main goals are to check the drug's safety and find the best dose. About 86 adults whose cancer has not responded to standard treatments will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Karmanos Cancer Institute

    RECRUITING

    Detroit, Michigan, 48201, United States

    Contact

  • Mary Crowley Cancer Research

    RECRUITING

    Dallas, Texas, 75230, United States

    Contact Email: •••••@•••••

    Contact

  • Next Oncology -Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact

    Contact Email: •••••@•••••

  • Oklahoma Univeristy

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The University of Texas M.D. Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.